Profil:
Selvita SASelvita pharma backlog for 2025 amounts to PLN 359.58 mln, up 8 pct y/y
Listed pharmaceuticals company Selvita's backlog for 2025 stands at PLN 359.58 million (EUR 77 mln), which is 8 percent higher year on year, the company said in a market filing.
Adjusted for the negative impact of a stronger zloty, growth would be around 10.3 percent.
In the Drug Discovery segment, the backlog totals PLN 257.5 million (EUR 55 mln, up by 3 percent year on year), while in Drug Development it amounts to PLN 96.3 million (EUR 21 mln, up by 20 percent year on year).
Ardigen's segment shows a year-on-year backlog increase of 9.5 percent to PLN 50.88 million (EUR 11 mln).
Below are the results of Selvita for the third quarter of 2025 with reference to the PAP Biznes consensus and previous results.
PLN mln
The reported results exclude EBITDA from the incentive program. The reported EBITDA for the third quarter of 2025 amounted to PLN 15.6 million (EUR 3.7 mln).
| 3Q2025 | results | consensus | difference | y/y | q/q | YTD 2025 | y/y |
| revenues | 89.6 | 89.0 | 0.7% | 0.1% | -5.7% | 276.2 | 11.4% |
| EBITDA adj. | 16.0 | 14.1 | 13.5% | 3.2% | 0.0% | 46.9 | 34.0% |
| EBIT | 2.3 | 0.1 | - | 64.3% | 43.8% | 4.1 | - |
| attrib. net profit | -0.9 | -2.9 | - | - | - | -6.5 | - |
| EBITDA margin | 17.9% | 15.9% | 1.96 | 0.54 | 1.02 | 16.98% | 2.86 |
| EBIT margin | 2.6% | 0.1% | 2.51 | 1.00 | 0.88 | 1.48% | 4.31 |
| net margin | -1.0% | -3.3% | 2.25 | -3.69 | 3.84 | -2.35% | 1.56 |
doa/ nl/ han/
